Latest News and Press Releases

Q1’24 revenue of $5.3M is up 340% vs. Q1’23 and at the midpoint of Lifeward’s guidance range Newly established Medicare payment for ReWalk Personal Exoskeleton favorably impacts Q1’24 results ...

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 07, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader...

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 19, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™) (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market lead...

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 12, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering...

Collaboration with CMS on final payment rate focuses on commercial transaction values for the latest generation of ReWalk Exoskeleton CMS indicates that recently issued fee schedule which omitted...

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 22, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader...

Reverse split initiated to regain compliance with Nasdaq listing requirements Financial guidance for 2024 and profitability target for 2026 on existing capital remain unchanged ...

Randomized clinical trial demonstrates significant improvements in walking ability for patients receiving therapy with the ReStore Exo-Suit as compared to a matched control group receiving...

The decision was communicated through CMS’ bi-annual Healthcare Common Procedure Coding System (“HCPCS”) coding memorandum released yesterday; payment amount determination for ReWalk Personal...

Highest quarterly and annual revenue in the history of LifewardCommercial and operational integration complete; synergiesexpected to yield $3 million in annual net savings MARLBOROUGH, Mass. and...